In an effort to lower drug prices, South Africa and Swiss pharmaceutical firm Lonza Group agreed last month to create a $211 million joint venture in Pretoria to manufacture chemicals used in drugs that treat HIV. In an email interview, Peter Navario, an adjunct associate professor of public policy at New York University and a former global health fellow at the Council on Foreign Relations, discussed South Africa’s HIV/AIDS policy.* WPR: How has South Africa’s HIV/AIDS policy evolved over the past 10 years? Peter Navario: Over the past 10 years, South Africa has gone from global laggard to playing a […]
Keep reading for free right now!
Enter your email to get instant access to the rest of this article, get three free articles every 30 days, and to receive our free email newsletter:
Or, Subscribe now to get full access.
Already a subscriber? Log in here .
What you’ll get with an All-Access subscription to World Politics Review:
A WPR subscription is like no other resource — it’s like having your own personal researcher and analyst for news and events around the globe. Subscribe now, and you’ll get:
- Immediate and instant access to the full searchable library of 15,000+ articles
- Daily articles with original analysis, written by leading topic experts, delivered to you every weekday
- Weekly in-depth reports on important issues and countries
- Daily links to must-read news, analysis, and opinion from top sources around the globe, curated by our keen-eyed team of editors
- Your choice of weekly region-specific newsletters, delivered to your inbox.
- Smartphone- and tablet-friendly website.
- Completely ad-free reading.
And all of this is available to you when you subscribe today.